Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Joshua Friedman(Icahn School of Medicine at Mount Sinai), Adı́lia Hormigo(Memorial Sloan Kettering Cancer Center), Kambiz Nael(University of California, San Francisco), Priyanka Kadaba(Icahn School of Medicine at Mount Sinai), Nadejda M. Tsankova(The University of Texas Southwestern Medical Center), Puneet Belani(Icahn School of Medicine at Mount Sinai), Ethan Ellis(Icahn School of Medicine at Mount Sinai), Tomi Jun(Sema4 (United States)), Omid Rashidipour(Icahn School of Medicine at Mount Sinai), Robert Sebra(Mount Sinai Hospital), Kuan‐lin Huang(Icahn School of Medicine at Mount Sinai)
Cited by 9
Related Papers
Negative feedback control of neuronal activity by microglia
|Nature|2020|997
Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
|Nature Communications|2017|153
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
|Cancer Cell|2022|127
Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma
|Nature Communications|2018|98
Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants
|Nature Communications|2023|98